Kaléo claims complex pricing structure will make allergy treatment 'available for millions'
Privately-held US pharma Kaléo has announced the relaunch date and details of an access program for its AUVI-Q (epinephrine injection, USP) auto-injector to treat life-threatening allergic reactions.
The alternative to the EpiPen (epinephrine) auto-injector, which has been sold by Netherlands-incorporated Mylan (Nasdaq: MYL) at prices which have drawn widespread criticism, will be available by prescription nationwide from February 14.
Kaléo has billed its AffordAbility access program as the first of its kind, claiming that it will offer 200 million Americans with commercial insurance, including those with high-deductible plans, the ability to obtain AUVI-Q for $0 out-of-pocket.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze